Cytokinetics, Incorporated (CYTK) - Financial and Strategic SWOT Analysis Review by GlobalData

VIEWS: 20 PAGES: 52

More Info
									              Cytokinetics, Incorporated (CYTK) - Financial and Strategic SWOT
                                       Analysis Review
        Reference Code: GDPH66590FSA                                                                                          Publication Date: APR 2013

          280 East Grand Avenue                              Phone              +1 650 6243000                  Revenue          7.6 (million USD)
          South San Francisco, CA                            Fax                +1 650 6243010                  Net Profit       -39.02 (million USD)
          94080                                              Website            www.cytokinetics.com            Employees        79 (Estimated)
                                                                                                                                 Pharmaceuticals           &
          United States                                      Exchange           CYTK [NASDAQ]                   Industry
                                                                                                                                 Healthcare

       Company Overview
       Cytokinetics, Incorporated (Cytokinetics) is a clinical stage biopharmaceutical company. The company carries out the discovery
       and development of innovative small molecule based therapeutics for modulation of muscle function for various diseases and
       medical conditions. The company focuses its research and development programs related to the biology of muscle function
       modulating the contractility of cardiac, skeletal and smooth muscle.
       Key Executives                                                                SWOT Analysis
                      Name                                 Title                      Cytokinetics, Incorporated, SWOT Analysis
         Robert I. Blum                      Chief Executive Officer                  Strengths                              Weaknesses
         Stephen Dow                         Director
                                                                                                                             Termination of Alliance with
         Dr. Denise        M.     Gilbert, Director                                   Patent Portfolio
                                                                                                                             GlaxosmithKline
         Ph.D.                                                                        Focused Research Activities
                                                                                                                             Weak Profitability Indicators
         Dr. L. Patrick Gage, Ph.D.          Director
         Santo J. Costa                      Director
        Source: Annual Report, Company Website, Primary and Secondary
                                                                                      Opportunities                          Threats
        Research, GlobalData
                                                                                      Orphan & Fast Track                    Competitive Landscape
       Share Data                                                                     Designations
                                                                                                                             Uncertain Research and
         Cytokinetics, Incorporated
                                                                                      Product Pipeline Portfolio             Development Activities
        Share Price (USD) as on 22-Apr-                                  1.40
        2013
                                                                                     Source: Annual Report, Company Website, Primary and Secondary Research,
        EPS (USD)                                                       -0.37        GlobalData
        Market Cap (million USD)                                         202
        Enterprise Value (million USD)                                   187
        Shares Outstanding (million)                                     144
       Source: Annual Report, Company Website, Primary and Secondary
       Research, GlobalData

       Financial Performance                                                         Recent Developments
                                                                                      Feb 05, 2013         Cytokinetics Reports Revenue Of $2.2m In Q4
                                                                                                           2012
                                                                                      Jan 25, 2013         Cytokinetics Receives NASDAQ Notice Of
                                                                                                           Minimum Bid Price Compliance
                                                                                      Dec 18, 2012         Cytokinetics Announces Listing Transfer From
                                                                                                           NASDAQ Global Market To NASDAQ Capital
                                                                                                           Market
                                                                                      Oct 30, 2012         Cytokinetics Reports Revenue Of $1.7m In Q3
                                                                                                           2012
       Source: Annual Report, Company Website, Primary and Secondary                 Source: Annual Report, Company Website, Primary and Secondary Research,
       Research, GlobalData                                                          GlobalData




Cytokinetics, Incorporated (CYTK) - Financial and Strategic SWOT                                                               Reference Code: GDPH66590FSA
Analysis Review
Source : www.globalcompanyintelligence.com                                                                                                                     Page 1
© GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form
       Table of Contents
       Table of Contents ............................................................................................................................................................................... 2
          List of Tables .................................................................................................................................................................................. 4
          List of Figures ................................................................................................................................................................................. 4
       Section 1 - About the Company.......................................................................................................................................................... 5
       Cytokinetics, Incorporated - Key Facts ............................................................................................................................................... 5
       Cytokinetics, Incorporated - Key Employees ...................................................................................................................................... 6
       Cytokinetics, Incorporated - Key Employee Biographies .................................................................................................................... 7
       Cytokinetics, Incorporated - Major Products and Services ................................................................................................................. 8
       Cytokinetics, Incorporated - Pharmaceutical Pipeline Products Data ................................................................................................. 9
          Cytokinetics, Incorporated, Pipeline Products by Therapy Area ..................................................................................................... 9
          Cytokinetics, Incorporated, Pipeline Products by Development Phase ......................................................................................... 10
       Cytokinetics, Incorporated - History.................................................................................................................................................. 13
       Cytokinetics, Incorporated - Company Statement ............................................................................................................................ 16
       Cytokinetics, Incorporated - Locations And Subsidiaries .................................................................................................................. 19
          Head Office ................................................................................................................................................................................... 19
       Section 2 – Company Analysis ......................................................................................................................................................... 20
       Cytokinetics, Incorporated - Business Description ........................................................................................................................... 20
       Cytokinetics, Incorporated - Corporate Strategy............................................................................................................................... 22
       Cytokinetics, Incorporated - SWOT Analysis .................................................................................................................................... 23
          SWOT Analysis - Overview........................................................................................................................................................... 23
          Cytokinetics, Incorporated - Strengths .......................................................................................................................................... 23
             Strength - Patent Portfolio ......................................................................................................................................................... 23
             Strength - Focused Research Activities .................................................................................................................................... 23
             Strength - Partnership with Amgen............................................................................................................................................ 23
          Cytokinetics, Incorporated - Weaknesses ..................................................................................................................................... 24
             Weakness - Termination of Alliance with GlaxosmithKline ........................................................................................................ 24
             Weakness - Weak Profitability Indicators .................................................................................................................................. 24
          Cytokinetics, Incorporated - Opportunities .................................................................................................................................... 24
             Opportunity - Orphan & Fast Track Designations ...................................................................................................................... 24
             Opportunity - Product Pipeline Portfolio .................................................................................................................................... 24
             Opportunity - Growth Potential: Oncology ................................................................................................................................. 25
             Opportunity - Demographic Trends ........................................................................................................................................... 25
          Cytokinetics, Incorporated - Threats ............................................................................................................................................. 25
             Threat - Competitive Landscape ............................................................................................................................................... 25
             Threat - Uncertain Research and Development Activities ......................................................................................................... 25
             Threat - Regulatory Environment .............................................................................................................................................. 26
       Cytokinetics, Incorporated - Key Competitors .................................................................................................................................. 27
       Section 3 – Company Financial Ratios ............................................................................................................................................. 28
       Financial Ratios - Capital Market Ratios........................................................................................................................................... 28
       Financial Ratios - Annual Ratios ...................................................................................................................................................... 28
       Performance Chart ........................................................................................................................................................................... 30
       Financial Performance...................................................................................................................................................................... 30
       Financial Ratios - Interim Ratios....................................................................................................................................................... 31
       Financial Ratios - Ratio Charts ......................................................................................................................................................... 32
       Section 4 – Company’s Lifesciences Financial Deals and Alliances ................................................................................................ 33


Cytokinetics, Incorporated (CYTK) - Financial and Strategic SWOT                                                                                               Reference Code: GDPH66590FSA
Analysis Review
Source : www.globalcompanyintelligence.com                                                                                                                                                                Page 2
© GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form
          Cytokinetics, Incorporated, Pharmaceuticals & Healthcare, Deals By Year, 2007 to YTD 2013................................................... 33
          Cytokinetics, Incorporated, Pharmaceuticals & Healthcare, Deals By Type, 2007 to YTD 2013 .................................................. 34
       Cytokinetics, Incorporated, Recent Deals Summary ........................................................................................................................ 35
       Section 5 – Company’s Recent Developments ................................................................................................................................ 36
          Cytokinetics, Incorporated, Recent Developments ....................................................................................................................... 36
             Feb 05, 2013: Cytokinetics Reports Revenue Of $2.2m In Q4 2012......................................................................................... 36
             Jan 25, 2013: Cytokinetics Receives NASDAQ Notice Of Minimum Bid Price Compliance ...................................................... 38
             Dec 18, 2012: Cytokinetics Announces Listing Transfer From NASDAQ Global Market To NASDAQ Capital Market ............. 38
             Oct 30, 2012: Cytokinetics Reports Revenue Of $1.7m In Q3 2012 ......................................................................................... 38
             Jul 31, 2012: Cytokinetics Reports Revenue Of $1.8m In Q2 2012 .......................................................................................
								
To top